BeOne Medicines AG (BVMF:B1ME34)
Brazil flag Brazil · Delayed Price · Currency is BRL
71.90
+0.71 (1.00%)
Last updated: Oct 10, 2025, 11:44 AM GMT-3
1.00%
Market Cap198.37B
Revenue (ttm)24.86B
Net Income (ttm)-967.93M
Shares Outn/a
EPS (ttm)-9.06
PE Ration/a
Forward PE60.58
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume108
Open71.90
Previous Close71.19
Day's Range71.90 - 71.90
52-Week Range41.50 - 72.45
Betan/a
RSI63.41
Earnings DateNov 13, 2025

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 11,000
Stock Exchange Brazil Stock Exchange
Ticker Symbol B1ME34
Full Company Profile

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.